Takahiro Yamanashi

Dr. Takahiro Yamanashi


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2018 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
KYKeigo Yokoi
Keigo Yokoi
HHHiroki Harada
Hiroki Harada
KYKazuko Yokota
Kazuko Yokota
SISatoru Ishii
Satoru Ishii
TTToshimichi Tanaka
Toshimichi Tanaka
Keishi YamashitaKeishi Yamashita
Keishi Yamashita

12 May 2022 in Asian Journal of Endoscopic Surgery
Verified
Journal Article
Open access
TYTakahiro Yamanashi
Takahiro Yamanashi
HMHirohisa Miura
Hirohisa Miura
TTToshimichi Tanaka
Toshimichi Tanaka
AWAkiko Watanabe
Akiko Watanabe
TGTakuya Goto
Takuya Goto
TNTakeshi Naitoh
Takeshi Naitoh
Introduction: The advantages of robotic‐assisted laparoscopic surgery (RALS) for rectal cancer remain controversial. This study clarified and compared the short‐term outcomes of RALS for rectal cancer with those of conventional laparoscopic surgery (CLS).Methods: The records of 303 consecutive patients who underwent RALS or CLS for rectal adenocarcinoma between November 2016 and November 2021 were analyzed using propensity score‐matched analysis. After matching, 188 patients were enrolled in our study to compare short‐term outcomes, such as operative results, postoperative complications, and pathological findings, in each group.Results: After matching, baseline characteristics were comparable between groups. Although operative time in the RALS group was significantly longer than in the CLS group (p < 0.0001), the conversion rate to open laparotomy and the postoperative complication rate in the RALS group were significantly lower than in the CLS group (p = 0.0240 and p = 0.0109, respectively). Blood loss was comparable between groups. In the RALS group, postoperative hospital stay and days to soft diet were significantly shorter than those in the CLS group (p = 0.0464 and p < 0.0001, respectively). No postoperative mortality was observed in either group and significant differences were observed in resection margins and number of lymph nodes harvested.Conclusion: Robotic‐assisted laparoscopic surgery for rectal cancer was safe, technically feasible, and had acceptable short‐term outcomes. Further studies are required to validate long‐term oncological outcomes.

21 November 2022 in Journal of Robotic Surgery
Verified
Journal Article
Open access
PDF file
TYTakahiro Yamanashi
Takahiro Yamanashi
HMHirohisa Miura
Hirohisa Miura
TTToshimichi Tanaka
Toshimichi Tanaka
AWAkiko Watanabe
Akiko Watanabe
KYKeigo Yokoi
Keigo Yokoi
TNTakeshi Naitoh
Takeshi Naitoh
The benefits of robot-assisted laparoscopic surgery (RALS) for rectal cancer remain controversial. Only a few studies have evaluated the safety and feasibility of RALS following neoadjuvant chemoradiotherapy (NCRT). This study aimed to compare the short-term outcomes of RALS versus conventional laparoscopic surgery (CLS) after NCRT for rectal cancer. Propensity score matching of 111 consecutive patients who underwent RALS or CLS after NCRT for rectal adenocarcinoma between February 2014 and February 2022 was performed. Among them, 60 matched patients were enrolled and their short-term outcomes were compared. Although operative time, conversion rate to open laparotomy and blood loss were comparable, the incidence of postoperative complications, including anastomotic leakage, was significantly lower, urinary retention tended to be lower, and the days to soft diet intake and postoperative hospital stay were significantly shorter in the RALS than the CLS group. No postoperative mortality was observed in either group, and there were no significant differences in terms of resection margins and number of lymph nodes dissected. RALS after NCRT for rectal cancer is safe and technically feasible, and has acceptable short-term outcomes. Further studies are required for validation of the long-term oncological outcomes.

16 June 2022 in Asian Journal of Endoscopic Surgery
Verified
Journal Article
Open access
TYTakahiro Yamanashi
Takahiro Yamanashi
HMHirohisa Miura
Hirohisa Miura
TTToshimichi Tanaka
Toshimichi Tanaka
AWAkiko Watanabe
Akiko Watanabe
TGTakuya Goto
Takuya Goto
TNTakeshi Naitoh
Takeshi Naitoh
Introduction: Whether rectal cancer surgery by robotic‐assisted laparoscopic surgery provides beneficial advantages remains controversial. Although favorable outcomes in terms of the safety and technical feasibility of robotic‐assisted laparoscopic surgery have been demonstrated for rectal cancer, long‐term oncological outcomes for robotic‐assisted laparoscopic surgery have only been examined in a few studies. This retrospective study of subjects who underwent robotic‐assisted laparoscopic surgery evaluated short‐ and long‐term outcomes of consecutive rectal cancer patients.Methods: Between November 2016 and January 2020, we analyzed the records of 62 consecutive patients who underwent robotic‐assisted laparoscopic surgery for rectal adenocarcinoma without distant metastasis to evaluate short‐ and long‐term outcomes.Results: Tumors were located in the lower or mid‐rectum (88.7%) in most patients. The median operative time was 357 min. No patient received transfusions, and the median blood loss was 10.5 ml. Open laparotomy was not required in any patient. A Clavien–Dindo classification of all grades was observed in 12 patients (19.4%). Positive radial margin was not observed in any patient. Duration of median follow‐up was 40.5 mo, while 3‐y overall survival and 3‐y relapse‐free survival rates were 96.8% and 85.0%, respectively. The local recurrence rate was 3.4%.Conclusion: Favorable short‐ and long‐term outcomes demonstrated robotic‐assisted laparoscopic surgery was safe and technically feasible for rectal cancer.

31 October 2025 in Cancers
Verified
Journal Article
Open access
PDF file
RORiku Okamoto
Riku Okamoto
KOKota Okuno
Kota Okuno
AWAkiko Watanabe
Akiko Watanabe
KNKanako Naito
Kanako Naito
HMHiroyuki Minoura
Hiroyuki Minoura
Keishi YamashitaKeishi Yamashita
Keishi Yamashita
Background/Objectives: To elucidate the differential transcriptional and intercellular signaling features of tumor components across various cancers, we conducted a comparative analysis using single-cell RNA sequencing (scRNA-seq). This technology enables detailed characterization of tumor ecosystems and may explain variations in tumor behavior among distinct cancer types. Methods: We analyzed publicly available scRNA-seq datasets (GEO) from seven cancer types—pancreatic ductal adenocarcinoma (PDAC), hepatocellular carcinoma (HCC), esophageal squamous cell carcinoma (ESCC), breast cancer (BC), thyroid cancer (TC), gastric cancer (GC), and colorectal cancer (CRC)—to define their unique molecular characteristics and intercellular interactions. Results: PDAC displayed a distinct tumor microenvironment (TME) dominated by myeloid cells (~42%), including abundant CXCR1/CXCR2-expressing tumor-associated neutrophils (TANs) that preferentially interacted with immune rather than cancer cells. The competitive receptor ACKR1 was minimally expressed on endothelial cells, consistent with PDAC hypo-vascularity. In HCC, tumor cells lacked EPCAM and expressed complement and stem cell markers; cancer-associated fibroblasts (CAFs) were scarce, and stellate cells expressed the pericyte marker RGS5. CAFs were abundant in ESCC and BC, with IGF1/2 expression, while in GC, these markers were uniquely found in plasma cells. Since BC and GC subtypes exhibit distinct TME patterns, it is necessary to perform subtype-specific analyses for these cancers. TC showed high expression of tumor-suppressor genes, including HOPX, in tumor cells. Differential interactions and the presence of “dominant signaling cell populations “ with dominant outgoing signals may underlie the heterogeneity in tumor aggressiveness across these cancers. Conclusions: Comparative scRNA-seq analysis of multiple cancers reveals distinct tumor phenotypes and cell–cell communication patterns, offering insights into the molecular architecture of human solid tumors.

9 July 2024 in Annals of Gastroenterological Surgery
Verified
Journal Article
Open access
KKKen Kojo
Ken Kojo
TYTakahiro Yamanashi
Takahiro Yamanashi
SHShigenori Homma
Shigenori Homma
MYManabu Yamamoto
Manabu Yamamoto
TMTakuya Miura
Takuya Miura
ESEnSSURE study group collaboratives in Japan Society of Laparoscopic Colorectal Surgery
EnSSURE study group collaboratives in Japan Society of Laparoscopic Colorectal Surgery
Background: In Japan, the Endoscopic Surgical Skill Qualification System (ESSQS) is used to evaluate surgical skills essential for laparoscopic surgery, but whether surgeons with this certification as operators improve the short‐term outcomes and prognosis after rectal cancer surgery is unclear. This cohort study was designed to compare the short‐term and long‐term outcomes of laparoscopic surgery for advanced rectal cancer performed by an ESSQS‐certified surgeon versus a surgeon without ESSQS certification.Methods: The outcomes of cStage II and III rectal cancer surgery cases performed at 56 Japanese hospitals between 2014 and 2016 were retrospectively reviewed. To examine the impact of ESSQS‐certified surgeons as surgeons, the outcomes of cases with only ESSQS‐certified surgeons as operators were compared with those without involvement of ESSQS‐certified surgeons.Results: A total of 3197 cases were enrolled, with 1015 in which surgery was performed by ESSQS‐certified surgeons, and 544 in which there was no involvement of ESSQS‐certified surgeons. After propensity score matching, the ESSQS group had significantly shorter operative time (p < 0.001), a lower conversion rate to open surgery (p < 0.001), and more dissected lymph nodes (p = 0.002).Conclusion: Laparoscopic rectal surgery performed by ESSQS‐certified surgeons was significantly associated with improved short‐term outcomes. This demonstrates the utility of the ESSQS certification system.